免疫治疗联合化疗在胃癌治疗中的研究进展
|
摘要
胃癌患者具有相对较高的突变负荷、新抗原基数和肿瘤浸润淋巴细胞,表明其对免疫治疗可能具有潜在应答性,但多项研究显示,免疫检查点程序性死亡受体1(programmed death protein1, PD-1)抑制剂单药治疗应答率仅为10%～26%。近期,人们对化疗对机体免疫系统的影响进行了深入探究,证实化疗药物可通过不同免疫调节机制对肿瘤免疫应答产生影响。多项研究显示,免疫治疗联合化疗药物在提高患者客观缓解率(ORR)和延长生存期方面具有一定成效,联合方案逐渐成为目前晚期胃癌研究的热点。本文主要阐述化疗药物对肿瘤免疫应答的影响、免疫治疗联合化疗在晚期胃癌中的应用及预测疗效的生物标记物的进展,以期为胃癌的临床治疗提供参考。
引文
[1]LAWRENCE M S,STOJANOV P,POLAK P,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J/OL].Nature,2013,499(7457):214-218[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919509/.DOI:10.1038/nature12213.
[2]LEE H E,CHAE S W,LEE Y J,et al.Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer[J/OL].Br J Cancer,2008,99(10):1704-1711[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584941/.DOI:10.1038/sj.bjc.6604738.
[3]王俊,王宝成.晚期胃癌免疫检查点抑制剂治疗的临床研究进展[J].中国肿瘤生物治疗杂志,2018,25(11):1089-1093.DOI:10.3872/j.issn.1007-385X.2018.11.001.
[4]KANG Y K,BOKU N,SATOH T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.DOI:10.1016/S0140-6736(17)31827-5.
[5]SHITARA K,BANG Y J,BARTOLOMEO M D,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061):a randomised,open-label,controlled,phase 3 tria[J]l.Lancet,2018,392(10142):S0140673618312571.DOI:10.1016/S0140-6736(18)31257-1.
[6]GALLUZZI L,BUQUéA,KEPP O,et al.Immunological effects of conventional chemotherapy and targeted anticancer agents[J].Cancer Cell,2015,28(6):690-714.DOI:10.1016/j.ccell.2015.10.012.
[7]ZITVOGEL L,GALLUZZI L,SMYTH M J,et al.Mechanism of action of conventional and targeted anticancer therapies:reinstating immunosurveillance[J].Immunity,2013,39(1):74-88.DOI:10.1016/j.immuni.2013.06.014.
[8]RAD A N,POLLARA G,SOHAIB S M,et al.The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation[J].Cancer Res,2003,63(16):5143-5150.
[9]RAMAKRISHNAN R,HUANG C,CHO H I,et al.Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy[J/OL].Cancer Res,2012,72(21):5483-5493[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577568/.DOI:10.1158/0008-5472.CAN-12-2236.
[10]VACCHELLI E,SENOVILLA L,EGGERMONT A,et al.Trial watch:Chemotherapy with immunogenic cell death inducers[J/OL].Oncoimmunology,2013,2(3):e23510[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655739/.DOI:10.4161/onci.23510.
[11]APETOH L,GHIRINGHELLI F,TESNIERE A,et al.The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J].Immunol Rev,2007,220:47-59.DOI:10.1111/j.1600-065X.2007.00573.x.
[12]SOMERSAN S,LARSSON M,FONTENEAU J F,et al.Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells[J].J Immunol,2001,167(9):4844-4852.
[13]MICHAUD M,MARTINS I,SUKKURWALA A Q,et al.Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice[J].Science,2011,334(6062):1573-1577.DOI:10.1126/science.1208347.
[14]PASQUIER E,KAVALLARIS M,ANDRéN.Metronomic chemotherapy:new rationale for new directions[J].Nat Rev Clin Oncol,2010,7(8):455-465.DOI:10.1038/nrclinonc.2010.82.
[15]EDDY PASQUIER,MARIA KAVALLARIS,NICOLAS ANDRé.Metronomic cheotherapy:new rationale for new directions[J].Nat Rev Clin Oncol,2010,7(8):455-465.DOI:10.1038/nrclinonc.2010.82.
[16]ZHAO H,FAN Y L,LI H,et al.Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma:a retrospective study of 165 patients[J].Cancer Biother Radiopharm,2013,28(4):303-309.DOI:10.1089/cbr.2012.1306.
[17]ZHANG L,MU Y,ZHANG A Q,et al.Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China:a meta-analysis of 29 trials involving 2,610 patients[J/OL].Oncotarget,2017,8(28):45164-45177[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542175/.DOI:10.18632/oncotarget.16665.
[18]LI L Y,LI W,WANG C,et al.Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma[J].Cytotherapy,2018,20(1):134-148.DOI:10.1016/j.jcyt.2017.09.009.
[19]WANG Y Z,WANG C,XIAO H J,et al.Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer[J/OL].Cancer Med,2017,6(1):45-53[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269688/.DOI:10.1002/cam4.942.
[20]CUI J W,LI L Y,WANG C,et al.Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma[J].Cytotherapy,2015,17(7):979-988.DOI:10.1016/j.jcyt.2015.03.605.[2`]JULIEN T,MARIA D B,ANTONIO C,et al.P-281JAVELIN Gastric 100:Phase 3 trial of avelumab(anti-PD-L1 antibody)maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable,locally advanced or metastatic gastric or gastroesophageal junction cancer[J].Ann Oncol,2016,27(suppl 2):ii81.3-ii82.DOI:10.1093/annonc/mdw199.271.
[21]WAINBERG Z A,JALAL S,MURO K,et al.LBA28PRKEYNOTE-059 Update:Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal(G/GEJ)cancer[J].Ann Oncol,2017,28(suppl_5):116-121.DOI:10.1093/annonc/mdx440.020.
[23]WANG Q Q,LIU F,LIU L.Prognostic significance of PD-L1 in solid tumor:An updated meta-analysis[J/OL].Medicine(Baltimore),2017,96(18):e6369[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419898/.DOI:10.1097/MD.0000000000006369.
[24]MUNARI E,ZAMBONI G,MARCONI M,et al.PD-L1 expression heterogeneity in non-small cell lung cancer:evaluation of small biopsies reliability[J/OL].Oncotarget,2017,8(52):90123-90131[201902-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685736/.DOI:10.18632/oncotarget.21485.
[25]MCLAUGHLIN J,HAN G,SCHALPER K A,et al.Quantitative assessment of the heterogeneity of PD-L1 expression in non-smallcell lung cancer[J/OL].JAMA Oncol,2016,2(1):46-54[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941982/.DOI:10.1001/jamaoncol.2015.3638.
[26]CHEN G,HUANG A C,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J/OL].Nature,2018,560(7718):382-386[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095740/.DOI:10.1038/s41586-018-0392-8.
[27]KIM S T,CRISTESCU R,BASS A J,et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-1458.DOI:10.1038/s41591-018-0101-z.
[2]LEE H E,CHAE S W,LEE Y J,et al.Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer[J/OL].Br J Cancer,2008,99(10):1704-1711[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584941/.DOI:10.1038/sj.bjc.6604738.
[3]王俊,王宝成.晚期胃癌免疫检查点抑制剂治疗的临床研究进展[J].中国肿瘤生物治疗杂志,2018,25(11):1089-1093.DOI:10.3872/j.issn.1007-385X.2018.11.001.
[4]KANG Y K,BOKU N,SATOH T,et al.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2017,390(10111):2461-2471.DOI:10.1016/S0140-6736(17)31827-5.
[5]SHITARA K,BANG Y J,BARTOLOMEO M D,et al.Pembrolizumab versus paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061):a randomised,open-label,controlled,phase 3 tria[J]l.Lancet,2018,392(10142):S0140673618312571.DOI:10.1016/S0140-6736(18)31257-1.
[6]GALLUZZI L,BUQUéA,KEPP O,et al.Immunological effects of conventional chemotherapy and targeted anticancer agents[J].Cancer Cell,2015,28(6):690-714.DOI:10.1016/j.ccell.2015.10.012.
[7]ZITVOGEL L,GALLUZZI L,SMYTH M J,et al.Mechanism of action of conventional and targeted anticancer therapies:reinstating immunosurveillance[J].Immunity,2013,39(1):74-88.DOI:10.1016/j.immuni.2013.06.014.
[8]RAD A N,POLLARA G,SOHAIB S M,et al.The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation[J].Cancer Res,2003,63(16):5143-5150.
[9]RAMAKRISHNAN R,HUANG C,CHO H I,et al.Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy[J/OL].Cancer Res,2012,72(21):5483-5493[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577568/.DOI:10.1158/0008-5472.CAN-12-2236.
[10]VACCHELLI E,SENOVILLA L,EGGERMONT A,et al.Trial watch:Chemotherapy with immunogenic cell death inducers[J/OL].Oncoimmunology,2013,2(3):e23510[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655739/.DOI:10.4161/onci.23510.
[11]APETOH L,GHIRINGHELLI F,TESNIERE A,et al.The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J].Immunol Rev,2007,220:47-59.DOI:10.1111/j.1600-065X.2007.00573.x.
[12]SOMERSAN S,LARSSON M,FONTENEAU J F,et al.Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells[J].J Immunol,2001,167(9):4844-4852.
[13]MICHAUD M,MARTINS I,SUKKURWALA A Q,et al.Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice[J].Science,2011,334(6062):1573-1577.DOI:10.1126/science.1208347.
[14]PASQUIER E,KAVALLARIS M,ANDRéN.Metronomic chemotherapy:new rationale for new directions[J].Nat Rev Clin Oncol,2010,7(8):455-465.DOI:10.1038/nrclinonc.2010.82.
[15]EDDY PASQUIER,MARIA KAVALLARIS,NICOLAS ANDRé.Metronomic cheotherapy:new rationale for new directions[J].Nat Rev Clin Oncol,2010,7(8):455-465.DOI:10.1038/nrclinonc.2010.82.
[16]ZHAO H,FAN Y L,LI H,et al.Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma:a retrospective study of 165 patients[J].Cancer Biother Radiopharm,2013,28(4):303-309.DOI:10.1089/cbr.2012.1306.
[17]ZHANG L,MU Y,ZHANG A Q,et al.Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China:a meta-analysis of 29 trials involving 2,610 patients[J/OL].Oncotarget,2017,8(28):45164-45177[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542175/.DOI:10.18632/oncotarget.16665.
[18]LI L Y,LI W,WANG C,et al.Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma[J].Cytotherapy,2018,20(1):134-148.DOI:10.1016/j.jcyt.2017.09.009.
[19]WANG Y Z,WANG C,XIAO H J,et al.Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer[J/OL].Cancer Med,2017,6(1):45-53[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269688/.DOI:10.1002/cam4.942.
[20]CUI J W,LI L Y,WANG C,et al.Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma[J].Cytotherapy,2015,17(7):979-988.DOI:10.1016/j.jcyt.2015.03.605.[2`]JULIEN T,MARIA D B,ANTONIO C,et al.P-281JAVELIN Gastric 100:Phase 3 trial of avelumab(anti-PD-L1 antibody)maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable,locally advanced or metastatic gastric or gastroesophageal junction cancer[J].Ann Oncol,2016,27(suppl 2):ii81.3-ii82.DOI:10.1093/annonc/mdw199.271.
[21]WAINBERG Z A,JALAL S,MURO K,et al.LBA28PRKEYNOTE-059 Update:Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal(G/GEJ)cancer[J].Ann Oncol,2017,28(suppl_5):116-121.DOI:10.1093/annonc/mdx440.020.
[23]WANG Q Q,LIU F,LIU L.Prognostic significance of PD-L1 in solid tumor:An updated meta-analysis[J/OL].Medicine(Baltimore),2017,96(18):e6369[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419898/.DOI:10.1097/MD.0000000000006369.
[24]MUNARI E,ZAMBONI G,MARCONI M,et al.PD-L1 expression heterogeneity in non-small cell lung cancer:evaluation of small biopsies reliability[J/OL].Oncotarget,2017,8(52):90123-90131[201902-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685736/.DOI:10.18632/oncotarget.21485.
[25]MCLAUGHLIN J,HAN G,SCHALPER K A,et al.Quantitative assessment of the heterogeneity of PD-L1 expression in non-smallcell lung cancer[J/OL].JAMA Oncol,2016,2(1):46-54[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941982/.DOI:10.1001/jamaoncol.2015.3638.
[26]CHEN G,HUANG A C,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J/OL].Nature,2018,560(7718):382-386[2019-02-22].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095740/.DOI:10.1038/s41586-018-0392-8.
[27]KIM S T,CRISTESCU R,BASS A J,et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-1458.DOI:10.1038/s41591-018-0101-z.